JPRN-UMIN000004255已完成未知
Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment - BEST study
Outpatient Oncology Unit, Kyoto University Hospital0 个研究点目标入组 80 人开始时间: 2010年9月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of using EGFR-TKI 2) Active infectious disease, active other severe diseases (uncontrollable hypertension, diabetes mellitus, cardiac disease, gastro-intestinal hemorrhage etc.) 3) Hemoptysis with 2.5mL or more bleeding tendency 4) Radiological findings of cavity lesion and/or central lesion and/or tumor invasion to major vessels 5) Cardiac and/or brain infarction within 6 months 6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 7) Brain metastasis expected bleeding 8) Ineterstitial pneumonitis on Chest CT 9) Impossible oral ingestion 10) Pleural or pericardial effusion, or ascites requiring treatment 11) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)on-Small Cell Lung CancerJPRN-UMIN000006459Kyushu University38
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)on-Small Cell Lung CancerJPRN-UMIN000006457Kyushu University30
尚未招募
2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001non-squamous non-small cell lung cancerJPRN-UMIN000011791Itabashi Chuo Medical Center16
已完成
2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancerJPRN-UMIN000016507Shizuoka cancer center21